Holen Sie sich die Stockscreener-App
1.035
0.49%
0.005
Schlusskurs vom Vortag:
$1.03
Offen:
$1.035
24-Stunden-Volumen:
80,407
Relative Volume:
0.14
Marktkapitalisierung:
$11.97M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-10.93M
KGV:
-0.7198
EPS:
-1.4378
Netto-Cashflow:
$-10.72M
1W Leistung:
-8.41%
1M Leistung:
-0.48%
6M Leistung:
-14.46%
1J Leistung:
-57.58%
1-Tages-Spanne:
$1.03
$1.06
1-Wochen-Bereich:
$1.02
$1.14
52-Wochen-Spanne:
$0.8127
$4.1899
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Firmenname
Phio Pharmaceuticals Corp
Sektor
Branche
Telefon
(508) 767-3861
Adresse
411 SWEDELAND ROAD, KING OF PRUSSIA, MA
Compare PHIO vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
1.03 | 11.97M | 0 | -10.93M | -10.72M | -1.4378 |
VRTX
Vertex Pharmaceuticals Inc
|
522.57 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
804.43 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,005.05 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.62 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
208.90 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-08-05 | Eingeleitet | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Aktie (PHIO) Neueste Nachrichten
Phio Pharmaceuticals Corp (NASDAQ: PHIO) Share Price, PHIO Stock News, PHIO Share Price & Updates - Kalkine
Phio Pharmaceuticals Corp (PHIOW) Key Financial Ratios – Valuation, Profitability & More - Value Research
PHIO Should I Buy - Intellectia AI
Phio Pharmaceuticals director Plott buys $17,100 in shares - Investing.com
Phio Pharmaceuticals director Plott buys $17,100 in shares By Investing.com - Investing.com Canada
Phio Pharmaceuticals (PHIO) director snaps up 15,000 shares - stocktitan.net
Price to sales forward of Phio Pharmaceuticals Corp. – NASDAQ:PHIO - TradingView
Phio Pharmaceuticals (PHIO) Chairman Robert Bitterman Buys 10,00 - GuruFocus
Phio Pharmaceuticals (PHIO) CEO boosts holdings to 431,421 shares - Stock Titan
Price to earnings forward of Phio Pharmaceuticals Corp. – NASDAQ:PHIO - TradingView
Price to earnings forward of Phio Pharmaceuticals Corp. – BOATS:PHIO - TradingView
Phio Pharmaceuticals Corp. SEC Filing (Aug 14, 2026) - Stock Titan
Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Compound PH-894 Targeting BRD4 Protein - The National Law Review
Phio Pharmaceuticals receives U.S. patent allowance for PH-894 By Investing.com - Investing.com Nigeria
Phio Pharmaceuticals receives U.S. patent allowance for PH-894 - Investing.com
Phio Pharma wins U.S. patent allowance for BRD4-targeting INTASYL compound PH-894 - Bitget
Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894 - TMX Newsfile
Phio Pharmaceuticals Receives U.S. Notice of Allowance for PH-894 Patent Targeting BRD4 Protein via INTASYL® Platform - kalkine.ca
Enterprise value to revenue forward of Phio Pharmaceuticals Corp. – NASDAQ:PHIO - TradingView
Phio Pharmaceuticals Corp (PHIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Phio Pharmaceuticals Corp. Q2 2026: Net income $(4.14)M, EPS $(0.36) — 10-Q Summary - TradingView
Phio Pharmaceuticals posts $4.1M Q2 net loss, cash $13.0M; advances PH-762 program - TradingView
PHIO: PH-762 clinical progress accelerates as cash runway extends into 2027 amid rising R&D costs - TradingView
PHIO: Q2 2026 net loss widened to $4.1M as PH-762 advanced, with $13M in cash and ongoing funding needs - TradingView
Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update - TMX Newsfile
Phio Pharmaceuticals advances PH-762 with comme... - Pluang
PHIO Q2'26 Earnings: EPS estimate is (0.36) USD - TradingView
Phio Pharmaceuticals (PHIO) Rises 2.91% as Shares Hold Above Key $1.01 SupportVolatility Skew - dars.gov.et
Phio Pharmaceuticals (NASDAQ:PHIO) secures patent milestone as PH-762 skin cancer program nears FDA meeting - Kalkine
PHIO Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series - TMX Newsfile
Phio Pharmaceuticals Corp (PHIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Phio Pharmaceuticals Corp (PHIO) Cash Flow - TradingKey
PHIO|Phio Pharmaceuticals Corp|Price:1.050| - TradingKey
TradingKey - TradingKey
Phio Pharmaceuticals Corp (PHIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Phio Pharmaceuticals Q1 2026 Earnings: Loss Widens as R&D Investments ContinueFinancial Summary - dars.gov.et
Phio Pharmaceuticals Market Sentiment - Benzinga España
Phio Pharmaceuticals Corp. Revenue Breakdown – NASDAQ:PHIO - TradingView
PHIO|Phio Pharmaceuticals Corp|Price:1.040| - TradingKey
PHIO|Phio Pharmaceuticals Corp|Price:1.055|Chg%:+0.015 - TradingKey
PHIO Q1 2026 Earnings: EPS Miss Widens as Clinical-Stage Biotech Continues to Advance PipelineWeak Earnings Momentum - vinanet.vn
Phio Pharmaceuticals (PHIO) Edges Higher, Testing Key Resistance at $1.13Sector ETF Flow - dars.gov.et
Phio Pharma corrects date for Renmark virtual non-deal roadshow presentation - Bitget
Phio Pharmaceuticals to present its INTASYL siR... - Pluang
Phio Pharmaceuticals CEO Robert Bitterman to Showcase INTASYL Gene Silencing Platform at Renmark Virtual Roadshow on July 28, 2026 - Kalkine Media
Phio Pharmaceuticals to Showcase INTASYL siRNA Platform and PH-762 Skin Cancer Therapy at Renmark Virtual Roadshow on July 28, 2026 - Kalkine Media
Phio Pharmaceuticals Appoints Dr. R. Todd Plott to Board of Directors, Strengthening Expertise in Dermatologic Research and Commercialization – Minichart - Minichart
Phio Pharmaceuticals appoints dermatologist to board By Investing.com - Investing.com South Africa
Phio Pharmaceuticals appoints dermatologist to board - Investing.com
Phio Pharmaceuticals adds dermatology expert to board - TipRanks
Finanzdaten der Phio Pharmaceuticals Corp-Aktie (PHIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Phio Pharmaceuticals Corp-Aktie (PHIO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Bitterman Robert J | Chairman, Pres. & CEO |
Aug 18 '26 |
Buy |
1.06 |
10,000 |
10,600 |
431,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Jun 26 '26 |
Buy |
0.99 |
10,000 |
9,900 |
421,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Dec 31 '25 |
Buy |
1.03 |
5,000 |
5,150 |
291,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Dec 23 '25 |
Buy |
1.02 |
5,000 |
5,100 |
286,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Nov 21 '25 |
Buy |
1.14 |
5,000 |
5,700 |
281,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Nov 18 '25 |
Buy |
1.27 |
5,000 |
6,350 |
276,421 |
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):